

Receipt date: 04/06/2007

10570737 - GAU: 1621



PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/570,737		
		Filing Date	September 8, 2004		
		First Named Inventor	Raphael Mechoulam		
		Art Unit	N/A		
		Examiner Name	N/A		
Sheet	1	of	4	Attorney Docket Number	0-06-058/16434/US/03

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	BISOGNO, TIZIANA et al., British Journal of Pharmacology, 134 (4):845-852 (2001) XP002319199	
	2	CASU, M. A. et al. (2003) Eur. J. Pharmacol. 459(1): 97-105	
	3	CHESHER, G. B. et al. (1973) Br. J. Pharmacol. 49(4): 588-94	
	4	COLOMBO, G. et al. (1998) Eur. J. Pharmacol. 344(1): 67-9	
	5	FRIDE, E. (1995) Brain Res. 697, 83	
	6	FRIDE, E. (2002) Endocannabinoids in the central nervous system - an overview. Prostaglandins, Leukotrienes and Essential Fatty Acids	
	7	FRIDE, E. and C. SANJUDO-PENA (2002) Cannabinoids and endocannabinoids: behavioral and developmental aspects. In: The Biology of Marijuana, ed. E. Onaivi, Harwood Academic Publishers, Reading	
	8	FRIDE, E. and R. MECOULAM (1993) Eur. J. Pharmacol. 231, 313	
	9	GALIEGUE, S. et al. (1995) Eur. J. Biochem. 232(1): 54-61	

Examiner Signature	/Brian Davis/	Date Considered	03/24/2010
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BD/

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/570,737		
		Filing Date	September 8, 2004		
		First Named Inventor	Raphael Mechoulam		
		Art Unit	N/A		
		Examiner Name	N/A		
Sheet	2	of	4	Attorney Docket Number	0-06-058/16434/US/03

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	GARDNER, A.L. et al. (1988) Trends Pharmacol. Sci. Suppl.: 40-3	
	11	GRIFFIN, G. et al. (1997) Eur. J. Pharmacol. 339, 53	
	12	GURWITZ, D. et al. (1994) Eur. J. Pharmacol. 267, 21	
	13	HAEFELY, W. et al. (1990) Trends Pharmacol. Sci. 11(11): 452-6	
	14	HANUS, L. et al. (1999) Proc. Natl. Acad. Sci. USA 96, 14228	
	15	HERKENHAM, M. (1995) Cannabinoid receptors, London, Academic Press: 145-166	
	16	IZZO, A. et al. (2000) Br. J. Pharmacol. 129(8): 1627-32	
	17	IZZO, A.A. et al. (2001) Br. J. Pharmacol. 132, 1411	
	18	JOHNSON, M.R. and MELVIN, L.S. (1986) The discovery of non-classical cannabinoids analgetics. In: Cannabinoids as therapeutic agents. Ed. R. Mechoulam, CRS Press FL, pp 121-145	
	19	LANDI, M. et al. (2002) Eur. J. Pharmacol. 450, 77	

Examiner Signature	/Brian Davis/	Date Considered	03/24/2010
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BD/

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/570,737		
		Filing Date	September 8, 2004		
		First Named Inventor	Raphael Mechoulam		
		Art Unit	N/A		
		Examiner Name	N/A		
Sheet	3	of	4	Attorney Docket Number	0-06-058/16434/US/03

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	20	MALFAIT, A.M. et al. (2000) Proc. Natl. Acad. Sci. USA 97, 9561	
	21	MARTIN, B. R. et al. (1991) Pharmacol. Biochem. Behav. 40(3): 471-8	
	22	MECHOULAM, R. et al. (1998) Prog. Med. Chem. 35, 199	
		MECHOULAM, R. CRS Press Fl. pp. 121-145	
	23	PARKER, L.A. et al. (2002) Neuroreport 13, 567	
	24	PERTWEE, R.G. (1997) Pharmacol. Ther. 74, 129	
	25	PERTWEE, R.G. (2001) Gut 48(6): 859-67	
	26	PINTO, L. (2002) Prostaglandins Leukot Essent Fatty Acids 66, 333	
	27	ROBSON, P. (2001) Br. J. Psychiatry 178, 107	
	28	TJOLSEN, A. and HOLE (1997) The Pharmacology of Pain, Springer, Heidelberg, pp.1-20]	

Examiner Signature	/Brian Davis/	Date Considered	03/24/2010
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BD/

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/570,737		
		Filing Date	September 8, 2004		
		First Named Inventor	Raphael Mechoulam		
		Art Unit	N/A		
		Examiner Name	N/A		
Sheet	4	of	4	Attorney Docket Number	0-06-058/16434/US/03

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	29	Young, J. M. et al. (1984) J. Invest. Dermatol. 82, 367-71	

Examiner Signature	/Brian Davis/	Date Considered	03/24/2010
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BD/